Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene

Journal of Gene Medicine

Volumn 5, Issue 6, 2003, Pages 518-527

  Errington, Stephen J ^a,b   Mann, Christopher J ^b   Fletcher, Sue ^b   Wilton, Stephen D ^b  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antisense oligonucleotides; Duchenne muscular dystrophy; Dystrophin; Exon skipping

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; MESSENGER RNA; MESSENGER RNA PRECURSOR; NUCLEOTIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; FLUORESCEIN ISOTHIOCYANATE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; EXON; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; MUSCLE FIBER CULTURE; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; RNA PROCESSING; RNA SPLICING; ANIMAL; CELL CULTURE; CELL NUCLEUS; CHEMISTRY; DRUG EFFECT; ENHANCER REGION; GENETICS; METABOLISM; MUSCLE CELL;

ANIMALS; CELL NUCLEUS; DYSTROPHIN; ENHANCER ELEMENTS (GENETICS); EXONS; FLUORESCEIN-5-ISOTHIOCYANATE; GENE TARGETING; HUMANS; MICE; MUSCLE FIBERS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA SPLICE SITES; RNA SPLICING; TUMOR CELLS, CULTURED;

EID: 0041688228     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.361     Document Type: Article

References (45)

1. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51 919-928.
2. Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989; 45: 498-506.
3. Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987; 50: 509-517.
4. Heald A, Anderson LV, Bushby KM, Shaw PJ. Becker muscular dystrophy with onset after 60 years. Neurology 1994; 44: 2388-2390.
5. Worton RG. Duchenne muscular dystrophy: gene and gene product; mechanism of mutation in the gene. J Inherit Metab Dis 1992; 15: 539-550.
6. Dai Y, Schwarz EM, Cu D, et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995; 92: 1401-1405.
7. Gussoni E, Blau HM, Kunkel LM. The late of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 1997; 3: 970-977.
8. Gussoni E, Soneoka Y, Strickland CD, et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999; 401: 390-394.
9. Budker V, Budker T, Zhang G, et al. Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process. J Gene Med 2000; 2: 76-88.
10. Culligan KG, Mackey AJ, Finn DM, Maguire PB, Ohlendieck K. Role of dystrophin isoforms and associated proteins in muscular dystrophy (review). Int J Mol Med 1998; 2: 639-648.
11. Fletcher S, Wilton SD, Howell JM. Gene therapy and molecular approaches to the treatment of hereditary muscular disorders. Curr Opin Neurol 2000; 13: 553-560.
12. Rando TA, Disatnik MH, Zhou LZ. Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. Proc Natl Acad Sci U S A 2000; 97: 5363-5368.
13. Kapsa R, Quigley A, Lynch GS, et al. In vivo and in vitro correction of the mdx dystrophin gene nonsense mutation by short-fragment homologous replacement. Hum Gene Ther 2001; 12 629-642.
14. Wilton SD, Lloyd F, Carville K, et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 1999; 9: 330-338.
15. Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A 2001; 98: 42-47.
16. Mann CJ, Honeyman K, McClorey G, Fletcher S, Wilton SD. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med 2002; 4: 644-654.
17. Agrawal S, Zhao Q. Antisense therapeutics. Curr Opin Chem Biol 1998; 2: 519-528.
18. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Therapeut 2002; 1: 347-355.
19. Agrawal S. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta 1999; 1489: 53-68.
20. van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001; 10: 1547-1554.
21. Aartsma-Rus A, Bremmer-Bout M, Janson A, et al. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 2002; 12: S71.
22. Matsuo M, Masumura T, Nakajima T, et al. A very small flame-shifting deletion within exon 19 of the Duchenne muscular dystrophy gene. Biochem Biophys Res Commun 1990; 170: 963-967.
23. Tanaka K, Watakabe A, Shimura Y. Polypurine sequences within a downstream exon function as a splicing enhancer. Mol Cell Biol 1994; 14: 1347-1354.
24. Takeshima Y, Nishio H, Sakamoto H, Nakamura H, Matsuo M. Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J Clin Invest 1995; 95: 515-520.
25. Pramono ZA, Takeshima Y, Alimsardjono H, et al. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun 1996; 226: 445-449.
26. Liu HX, Zhang M, Krainer AR. Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins. Genes Dev 1998; 12: 1998-2012.
27. Xu R, Teng J, Cooper TA. The cardiac troponin T alternative exon contains a novel purine-rich positive splicing element. Mol Cell Biol 1993; 13: 3660-3674.
28. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984; 81: 1189-1192.
29. Morgan JE, Beauchamp JR, Pagel CN, et al. Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 1994; 162: 486-498.
30. Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 1994; 125: 1275-1287.
31. Wilton SD, Lim L, Dye D, Laing N. Bandstab: a PCR-based alternative to cloning PCR products. Biotechniques 1997; 22: 642-645.
32. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 1998; 7 1083-1090.
33. Maquat LE. When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells. Rna 1995; 1: 453-465.
34. Stein CA, Krieg AM. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev 1994; 4: 67-69.
35. Feener CA, Koenig M, Kunkel LM. Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus. Nature 1989; 338: 509-511.
36. Sadoulet-Puccio HM, Kunkel LM. Dystrophin and its isoforms. Brain Pathol 1996; 6: 25-35.
37. Anderson MS, Kunkel LM. The molecular and biochemical basis of Duchenne muscular dystrophy. Trends Biochem Sci 1992; 17: 289-292.
38. Zubrzycka-Gaarn EE, Hutter OF, Karpati G, et al. Dystrophin is tightly associated with the sarcolemma of mammalian skeletal muscle fibers. Exp Cell Res 1991; 192: 278-288.
39. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 1993; 90: 3710-3714.
40. Roberts RG, Bobrow M, Bentley DR. Point mutations in the dystrophin gene. Proc Natl Acad Sci U S A 1992; 89: 2331-2335.
41. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988; 2: 90-95.
42. Chelly J, Kaplan JC, Maire P, Gautron S, Kahn A. Transcription of the dystrophin gene in human muscle and non-muscle tissue. Nature 1988; 333: 858-860.
43. Furdon PJ, Dominski Z, Kole R. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res 1989; 17: 9193-9204.
44. Takeshima Y, Wada H, Yagi M, et al. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev 2001; 23: 788-790.
45. Tennyson CN, Klamut HJ, Worton RG. The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced. Nat Genet 1995; 9: 184-190.